IgE and IgG antibody responses to recombinant Alt a 1 as a marker of sensitization to Alternaria in asthma and atopic dermatitis.
IgE and IgG antibody responses to recombinant Alt a 1 as a marker of sensitization to Alternaria in asthma and atopic dermatitis.
复制标题
IgE 和 IgG 抗体对重组 Alt a 1 的反应，作为哮喘和特应性皮炎中链格孢属过敏的标志物。
DOI：
10.1046/j.1365-2222.2001.00745.x
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Chapman,MD
中科院分区：
文献类型：
--
作者：
Vailes,LD;Perzanowski,MS;Wheatley,LM;Platts-Mills,TA;Chapman,MD
研究背景对链格孢菌的致敏作用是引起喘息和哮喘的危险因素。Alt a1是引起哮喘患者致敏的主要链格孢变应原。一些特应性皮炎（AD）患者具有非常高的抗链格孢菌的免疫球蛋白（IG）E抗体（ab），然而，本研究的目的是分析哮喘和AD患者对重组Alt a1的特异性IgE和IgG ab应答，并将这些结果与IgE ab进行比较，方法从58例哮喘/鼻炎患者，19例AD患者，用放射免疫分析法（RIA）测定了43例哮喘患者和20例囊性纤维化（CF）患者的IgE和IgG抗体，并与对照组进行比较。在AlternariaCAP评分> 2的鼻炎患者 中，高百分比（93%）具有针对Alt α 1的IgE和IgG抗体，强调了其作为主要过敏原的重要性。只有47%的CAP评分大于2的AD患者具有ab至Alt a 1，与哮喘患者相比，他们的水平较低。CF对照组中75%的患者ALT a 1抗体阴性，RIA阳性者CAP也阳性。CAP低（1-2）的哮喘患者，ALT a1的IgE和IgG抗体阳性率较低（20-30%）。结论哮喘患者ALT a1的IgE和IgG抗体阳性率可作为链格孢菌致敏的良好指标。尽管AD患者的AlternariaCAP评分较高，但他们的Alt a 1 IgE水平较低或检测不到，这表明其他Alternaria变应原可能在AD中很重要，或者CAP结果是非特异性的。重组过敏原可能提供更具体的措施致敏真菌。
BackgroundSensitization toAlternaria alternatais a risk factor for the development of wheezing and asthma. Alt a 1 is the majorAlternariaallergen causing sensitization in asthmatics. Some atopic dermatitis (AD) patients have very high immunoglobulin (Ig)E antibody (ab) toAlternariaas analysed by Pharmacia CAP, however, it is not clear whether these are specific responses or whether Alt a 1 is involved in disease symptoms.ObjectiveThe aim of this study was to analyse specific IgE and IgG ab responses to recombinant Alt a 1 in asthmatic and AD patients and to compare these results to IgE ab againstAlternariameasured by CAP.MethodsSera from individuals who were IgE positive toAlternariaby CAP were obtained from 58 patients with asthma/rhinitis, 19 patients with AD, and 20 patients with cystic fibrosis (CF) who were included as specificity controls.IgE and IgG ab to recombinant Alt a 1 were measured by radioimmunoassay (RIA).ResultsOf 43 asthma/rhinitis patients having anAlternariaCAP score > 2, a high percentage (93%) had both IgE and IgG ab to Alt a 1, emphasizing its importance as a major allergen. Only, 47% of AD patients with CAP score greater than 2 had ab to Alt a 1, and their levels were low when compared to the asthmatics. For CF controls, 75% of these patients had no IgE ab to Alt a 1, and those which were positive to Alt a 1 by RIA were also positive by CAP. Overall, patients with a low CAP (1–2) had a low prevalence (20–30%) of IgE or IgG ab to Alt a 1.ConclusionIgE and IgG ab to Alt a 1 in asthmatics are good markers for sensitization toAlternaria. Although AD patients gave highAlternariaCAP scores, they had low or undetectable levels of IgE to Alt a 1, suggesting that otherAlternariaallergens may be important in AD or that the CAP results are non‐specific. Recombinant allergens may provide more specific measures of sensitization to fungi.